DavidL.GrinblattMD

Hematology • Evanston, IL

Physician

Join to view full profile

Dr. Grinblatt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Grinblatt's full profile

Already have an account?

Office
2650 Ridge Ave
# Kellogg
Evanston, IL 60201
Phone+1 847-570-2112

Fax+1 847-570-1041

Education & Training

McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1989 - 1990
Rush University Medical CenterResidency, Internal Medicine, 1986 - 1989
Case Western Reserve University School of MedicineClass of 1986

Certifications & Licensure

IL State Medical License 1986 - 2026
OH State Medical License 1986 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com

Clinical Trials

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Start of enrollment: 1996 Dec 01
Completed
Phase 1, Phase 2
Topotecan in Treating Patients With Myelodysplastic Syndrome Start of enrollment: 1999 Mar 01
Completed
Phase 2
Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Start of enrollment: 2001 Jul 01
Completed
Phase 2
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2007 Jul 24
Terminated
Phase 1, Phase 2
AVIDA The Vidaza® (Azacitidine) Patient Registry Start of enrollment: 2006 Oct 31
Completed
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

18 citations
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Re...
Benjamin A Derman, Ankit Kansagra, Jeffrey Zonder, Andrew T Stefka, David L Grinblatt
JAMA Oncology. 2022-09-01
11 citations
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in pat...
Xavier Poiré, Justin Kline, David L. Grinblatt, Todd M. Zimmerman, Kathy Conner
Leukemia & Lymphoma. 2010-06-24
27 citations
Azacitidine in Lower‐Risk Myelodysplastic Syndromes: A Meta‐Analysis of Data from Prospective Studies
Rami S. Komrokji, Arlene S. Swern, David L. Grinblatt, Roger M. Lyons, Magnus Tobiasson
The Oncologist. 2018-02-01

Lectures

Pediatric Review
The Osler Institute, Chicago, Illinois - 4/25/2013

Grant Support

Community Clinical Oncology ProgramNational Cancer Institute2011
Community Clinical Oncology ProgramNational Cancer Institute2006–2010

Professional Memberships

American Society of Clinical Oncology - ASCO
Member